COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES
OBJECTIVES: To assess cost effectiveness of anticoagulant clinics after FDA approval of New Oral Anticoagulants (NOACs) for preventing ischemic stroke in Atrial Fibrillation (AF) patients in the United States. METHODS: A decision tree was built to compare cost and effectiveness of 150mg dabigatran t...
Main Author: | |
---|---|
Format: | Others |
Published: |
VCU Scholars Compass
2015
|
Subjects: | |
Online Access: | http://scholarscompass.vcu.edu/etd/3883 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=4923&context=etd |
id |
ndltd-vcu.edu-oai-scholarscompass.vcu.edu-etd-4923 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-vcu.edu-oai-scholarscompass.vcu.edu-etd-49232017-03-17T08:28:28Z COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES Alhazami, Mai OBJECTIVES: To assess cost effectiveness of anticoagulant clinics after FDA approval of New Oral Anticoagulants (NOACs) for preventing ischemic stroke in Atrial Fibrillation (AF) patients in the United States. METHODS: A decision tree was built to compare cost and effectiveness of 150mg dabigatran twice a day to adjusted dose of warfarin within anticoagulation clinic. The analysis was for one year using a societal perspective. The population in this analysis was a cohort of AF patients, ≥ 65 years old, with a CHADS2 score>2, and no contraindication to anticoagulation. RESULTS: The base case analysis showed that changing from warfarin with anticoagulant clinic to dabigatran without monitoring resulted in an additional $82,793 per QALY saved. Sensitivity analyses found that the model was sensitive to utilities of patients on warfarin. CONCLUSION: This study showed that substituting dabigatran for warfarin in this population was not within acceptable willingness to pay values for new therapy. 2015-01-01T08:00:00Z text application/pdf http://scholarscompass.vcu.edu/etd/3883 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=4923&context=etd © The Author Theses and Dissertations VCU Scholars Compass economic anticoagulants warfarin NOACs cost effectiveness Medicine and Health Sciences Pharmacy and Pharmaceutical Sciences |
collection |
NDLTD |
format |
Others
|
sources |
NDLTD |
topic |
economic anticoagulants warfarin NOACs cost effectiveness Medicine and Health Sciences Pharmacy and Pharmaceutical Sciences |
spellingShingle |
economic anticoagulants warfarin NOACs cost effectiveness Medicine and Health Sciences Pharmacy and Pharmaceutical Sciences Alhazami, Mai COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES |
description |
OBJECTIVES: To assess cost effectiveness of anticoagulant clinics after FDA approval of New Oral Anticoagulants (NOACs) for preventing ischemic stroke in Atrial Fibrillation (AF) patients in the United States. METHODS: A decision tree was built to compare cost and effectiveness of 150mg dabigatran twice a day to adjusted dose of warfarin within anticoagulation clinic. The analysis was for one year using a societal perspective. The population in this analysis was a cohort of AF patients, ≥ 65 years old, with a CHADS2 score>2, and no contraindication to anticoagulation. RESULTS: The base case analysis showed that changing from warfarin with anticoagulant clinic to dabigatran without monitoring resulted in an additional $82,793 per QALY saved. Sensitivity analyses found that the model was sensitive to utilities of patients on warfarin. CONCLUSION: This study showed that substituting dabigatran for warfarin in this population was not within acceptable willingness to pay values for new therapy. |
author |
Alhazami, Mai |
author_facet |
Alhazami, Mai |
author_sort |
Alhazami, Mai |
title |
COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES |
title_short |
COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES |
title_full |
COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES |
title_fullStr |
COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES |
title_full_unstemmed |
COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES |
title_sort |
cost effectiveness of warfarin in anticoagulant clinic after introduction of dabigatran for stroke prevention in atrial fibrillation patients in the united states |
publisher |
VCU Scholars Compass |
publishDate |
2015 |
url |
http://scholarscompass.vcu.edu/etd/3883 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=4923&context=etd |
work_keys_str_mv |
AT alhazamimai costeffectivenessofwarfarininanticoagulantclinicafterintroductionofdabigatranforstrokepreventioninatrialfibrillationpatientsintheunitedstates |
_version_ |
1718428581121490944 |